DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Enhancement of Antiviral Agents Through the Use of Controlled-Release Technology
Technical Report,01 Nov 1985,31 Jan 1987
SOUTHERN RESEARCH INST BIRMINGHAM AL BIRMINGHAM United States
Pagination or Media Count:
This First Annual Progress Report covers research completed during the period from November 1, 1985, through January 31, 1987. The major objectives of this research program are a To develop a programmed-release delivery system microcapsule system designed to enhance the immunogenic potential of an inactivated killed Japanese Encephalitis JE virus vaccine, allowing for immunization against this viral agent and, b To develop controlled-release microcapsule delivery systems that will enhance the effects of the following immune modulators and antiviral agents muramyl tripeptide MTP, interferon IFN, and polyriboinosinic acid-ribocytidylic acid polyI.C. More specifically, we are involved in the development of biocompatible, biodegradable, controlled-release microcapsule formulation to release polyI.C, interferon IFN, and JE vaccine at controlled rates after a single intramuscular or intravenous administration. We also plan to develop microcapsule formulations that will target the release of MTP to macrophages, causing macrophage activation and subsequent nonimmune protection against active viral infections. We have prepared and characterized four batches of polyDL-lactide-co-glycolide to be used as the polymeric excipients in the microencapsulation work. In addition, we have actively pursued development and testing of polyI.C and Je vaccine microcapsule formulations.
APPROVED FOR PUBLIC RELEASE